



US009408837B2

(12) **United States Patent**  
**Hoyle et al.**

(10) **Patent No.:** **US 9,408,837 B2**  
(45) **Date of Patent:** **\*Aug. 9, 2016**

(54) **AMELIORATING DRUG-INDUCED ELEVATIONS IN BLOOD PRESSURE BY ADJUNCTIVE USE OF ANTIHYPERTENSIVE DRUGS**

(75) Inventors: **Peter C. Hoyle**, Lovettsville, VA (US);  
**Paul Waymack**, Washington, DC (US)

(73) Assignee: **Kitov Pharmaceutical Ltd.**, Jerusalem (IL)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 282 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/026,741**

(22) Filed: **Feb. 14, 2011**

(65) **Prior Publication Data**

US 2011/0136793 A1 Jun. 9, 2011

#### **Related U.S. Application Data**

(63) Continuation-in-part of application No. 12/990,724, filed as application No. PCT/US2009/044966 on May 22, 2009.

(60) Provisional application No. 61/304,243, filed on Feb. 12, 2010, provisional application No. 61/320,477, filed on Apr. 2, 2010, provisional application No. 61/056,789, filed on May 28, 2008, provisional application No. 61/097,972, filed on Sep. 18, 2008.

(51) **Int. Cl.**

**A61K 31/18** (2006.01)  
**A61K 31/192** (2006.01)  
**A61K 31/415** (2006.01)  
**A61K 31/4439** (2006.01)  
**A61K 31/4418** (2006.01)  
**A61K 31/165** (2006.01)  
**A61K 31/5377** (2006.01)  
**A61K 31/4422** (2006.01)  
**A61K 31/137** (2006.01)  
**A61K 31/549** (2006.01)  
**A61K 9/00** (2006.01)  
**A61K 31/635** (2006.01)  
**A61K 47/12** (2006.01)  
**A61K 47/26** (2006.01)  
**A61K 47/36** (2006.01)

(52) **U.S. Cl.**

CPC ..... **A61K 31/4422** (2013.01); **A61K 9/0053** (2013.01); **A61K 31/137** (2013.01); **A61K 31/165** (2013.01); **A61K 31/192** (2013.01); **A61K 31/4418** (2013.01); **A61K 31/549** (2013.01); **A61K 31/635** (2013.01); **A61K 47/12** (2013.01); **A61K 47/26** (2013.01); **A61K 47/36** (2013.01); **A61K 31/18** (2013.01)

(58) **Field of Classification Search**

CPC ..... **A61K 31/292**; **A61K 31/415**; **A61K 31/4439**; **A61K 31/4418**; **A61K 31/5377**; **A61K 31/165**; **A61K 31/18**  
See application file for complete search history.

(56) **References Cited**

#### **U.S. PATENT DOCUMENTS**

6,057,344 A \* 5/2000 Young ..... 514/356  
6,323,226 B1 11/2001 Delgado et al.  
2004/0186155 A1 9/2004 Dayno et al.  
2006/0160834 A1 7/2006 Fong et al.  
2006/0177504 A1 8/2006 Sundharadas

#### **FOREIGN PATENT DOCUMENTS**

WO 2006102476 9/2006  
WO WO 2007-021460 2/2007

#### **OTHER PUBLICATIONS**

Huston, M. C., "Nonsteroidal anti-inflammatory drugs and antihypertensives". American Journal of medicine, Excerpta Medica, Inc, United States. vol. 90, No. 5, May 17, 1991. pp. S42-S47, XP023307988, ISSN: 0002-9343.

Arellano, F.M., et al., "Use of Cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDs) in UK and USA populations. Implication for COX-2 cardiovascular profile." Pharmacoeconomics and Drug Safety. 2006, vol. 15, No. 12, pp. 861-872, ISSN 1053-8569, See the whole document.

Huerta, C., et al., "Nonsteroidal anti-inflammatory drugs and risks of ARF in the general population." American Journal of Kidney Disease. 2005, vol. 45, No. 3, pp. 531-539, ISSN 0272-6386, See the whole document.

(Continued)

*Primary Examiner* — Samira Jean-Louis

(74) *Attorney, Agent, or Firm* — Whitham, Curtis & Cook, P.C.

(57) **ABSTRACT**

Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies.

**3 Claims, No Drawings**